Purpose: To examine the prognostic value of cone-beam computed tomography (CBCT)–based tumor enhancement parameters at predicting treatment response and overall survival after hepatic art...
Purpose: Hepatic resection and ablation are standard of care for patients with hepatocellular carcinoma (HCC), but although potentially curative, the risk of recurrence is high (44%–79% a...
Purpose: Accurate image-guided ablation of liver tumors larger than 3 cm in diameter is compromised by the difficulty to visualize the achieved zone of ablation in relation to the target....
Purpose: To examine the diagnostic yield and predictive factors of biopsy adequacy of intraprocedural percutaneous biopsy performed at the time of radiofrequency ablation of osteoid osteo...
Purpose: Because curative therapy is not always feasible and there is no standard systemic therapy, patients with intermediate-stage hepatocellular carcinoma (HCC) are treated with locore...
Purpose: To provide an overview of challenges in percutaneous access of the hepatic dome lesions and discuss current maneuvers and techniques facilitating technical success and safety dur...
Purpose: To illustrate the utility of a continuous aspiration mechanical thrombectomy catheter in the tissue-proven determination and retrieval of hepatocellular carcinoma (HCC) tumor thr...
Purpose: The purpose of the study is to systematically review the roles of CA 19-9 combined with positron emission tomography/computed tomography (PET/CT) and radiofrequency ablation as a...
Purpose: Hepatocellular carcinoma (HCC) is the most deadly primary hepatic cancer in the pediatric population. Although interventional radiology is not a mainstay of treatment currently, ...
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Siemens Healthineers and University Hospitals Cleveland News
Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
Embolization is a minimally invasive...
